endothelin-converting enzyme

pH optimum 3.5; cathepsin D-like aspartic protease; inhibited by pepstatin; ECE-1 is a metalloproteinase that catalyzes proteolytic activation of big endothelin-1; RefSeq NM_001397 (ECE1, human), NM_199307 (Ece1, mouse); NM_139293 (Ece2, mouse); NM_014693 (ECE2, human)
Also Known As:
ECE-1 protein, human; ECE-1beta; ECE-2; ECE-2 protein; ECE-2 protein, human; ECE1 protein, human; ECE2 protein, human; Ece1 protein, mouse; Ece2 protein, mouse; Endothelin-converting enzyme 1; Endothelin-converting enzyme 2; endothelin converting enzyme; endothelin converting enzyme 1, human; endothelin converting enzyme 1, mouse; endothelin converting enzyme 2, human; endothelin converting enzyme 2, mouse; endothelin converting enzyme II; endothelin converting enzyme-1a; endothelin converting enzyme-2; endothelin-converting enzyme-1b; endothelin-converting enzyme-2; endothelin-converting metalloprotease 2; metalloprotease ECE-2
Networked: 137 relevant articles (6 outcomes, 21 trials/studies)

Relationship Network

Bio-Agent Context: Research Results


1. Jeng, Arco Y: 9 articles (11/2010 - 08/2002)
2. Kwan, Aij-Lie: 6 articles (03/2007 - 08/2002)
3. Hocher, Berthold: 4 articles (06/2011 - 11/2004)
4. Naruko, Takahiko: 4 articles (03/2008 - 05/2004)
5. Tanzawa, Kazuhiko: 4 articles (03/2008 - 01/2003)
6. Ueda, Makiko: 4 articles (03/2008 - 05/2004)
7. Ikura, Yoshihiro: 4 articles (03/2008 - 05/2004)
8. Kassell, Neal F: 4 articles (03/2007 - 08/2002)
9. Wu, Shu-Chuan: 4 articles (03/2007 - 08/2002)
10. Matsumura, Yasuo: 3 articles (05/2011 - 09/2008)

Related Diseases

1. Muscle Spasticity (Spastic)
2. Hypertension (High Blood Pressure)
3. Ischemia
02/01/2011 - "As ET-1 is generated from big ET-1 via endothelin-converting enzyme (ECE), ischemia/reperfusion-induced cardiac injury may be exacerbated by exogenous big ET-1. "
05/01/2011 - "We have recently shown that an appropriate amount of exogenous big endothelin-1 (ET-1) has beneficial effects on ischemia-/reperfusion-induced norepinephrine overflow and cardiac dysfunction in rat hearts and that these effects occur through a conversion to ET-1 by endothelin-converting enzyme and following stimulation of ETB receptor. "
11/01/2002 - "To evaluate the effect of the combination of N-acetylcysteine (NAC), a potent antioxidant, sodium nitroprusside (SNP), a nitric oxide donor, and phosphoramidon (P), an endothelin converting enzyme inhibitor, on tissue protection against ischemia-reperfusion injury, we studied the biochemical and morphological changes due to 90 min of renal ischemia-reperfusion in the rat model. "
09/04/2008 - "The aim of this study was to investigate the role of endogenously generated endothelin-1 in ischemia/reperfusion-induced norepinephrine overflow and cardiac dysfunction using a nonselective prototype of endothelin-converting enzyme (ECE) inhibitor, phosphoramidon, and a selective ECE inhibitor, SM-19712 (4-chloro-N-[[(4-cyano-3-methyl-1-phenyl-1H-pyrazol-5-yl)amino]carbonyl]benzenesulfonamide, monosodium salt). "
10/01/1998 - "In this study, the effects of BQ123 (an ET(A) receptor antagonist), bosentan (a nonselective ET(A)-ET(B) antagonist), and phosphoramidon (an endothelin converting enzyme inhibitor) were investigated on intestinal mucosal lesion formation and changes in tissue PGE2 and LTC4 levels due to intestinal ischemia-reperfusion (I/R) injury in rats. "
4. Pulmonary Hypertension (Ayerza Syndrome)
5. Reperfusion Injury

Related Drugs and Biologics

1. phosphoramidon
2. Endothelin-1 (Endothelin 1)
3. Neprilysin (Neutral Endopeptidase)
4. Endothelin Receptors (Endothelin Receptor)
5. chelerythrine
6. Nitroprusside (Sodium Nitroprusside)
7. Nitric Oxide (Nitrogen Monoxide)
8. Acetylcysteine (Siran)
9. Y 27632
10. CGS 26303

Related Therapies and Procedures

1. Transplants (Transplant)
2. Intravenous Infusions
3. Microspheres (Microsphere)
4. Immunomodulation
5. Homologous Transplantation (Allograft)